Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

IMPORTANCE: Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Shoushtari, Alexander N., Friedman, Claire F., Navid-Azarbaijani, Pedram, Postow, Michael A., Callahan, Margaret K., Momtaz, Parisa, Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833656/
https://ncbi.nlm.nih.gov/pubmed/28817755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2391
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados